Auditory Translational Research
Kathleen CM Campbell, PhD is Professor and Director of Audiology Research at SIU School of Medicine in Springfield, IL. She conducts translational research discovering, patenting, and developing pharmacologic otoprotective agents to prevent or provide rescue from noise-induced hearing loss and tinnitus, to prevent cisplatin-induced hearing loss and both central and peripheral neuropathy, radiation-induced oral mucositis, and aminoglycoside induced hearing loss and vestibular disorders. The focus of her current laboratory studies include optimizing D-methionine dosing to prevent and provide rescue from noise-induced hearing loss and tinnitus, to determine the maximum length of time that pharmacologic intervention can be effective after noise cessation, and to determine optimal D-methionine dosing in preparation for clinical trials to prevent aminoglycoside induced hearing loss and vestibular disorders. She has successfully completed clinical trials to prevent cisplatin-induced hearing loss and radiation induced oral mucositis. She is funded by the Department of Defense to conduct clinical trials using D-methionine to prevent noise-induced hearing loss. Her currently active funding from the National Institutes of Health and the US Department of Defense exceeds 6 million dollars.
Hope for Hearing Loss
Hearing is essential for a good quality of life. For some patients, even the best hearing aids aren’t strong enough. For deployed military personnel, noise induced hearing loss (NIHL) is a daily possibility. NIHL is the most common reason that some U.S. soldiers cannot be redeployed. - See more at:
SIU Med School Hearing Loss Study Advances with DOD Grant
A Southern Illinois University School of Medicine patented drug aimed at preventing noiseinduced hearing loss is in the final stages of research. A $2.5 million grant from the U.S. Department of Defense U.S. Army Research and Materiel Command Branch will support a Phase 3 clinical trial to determine if D-methionine (D-met) can prevent noise-induced hearing loss in soldiers.
Kathleen C.M. Campbell, Ph.D., SIU professor of otolaryngology head and neck surgery and director of the division’s audiology research, is the principal investigator for the five-year project and inventor of the D-met drug. The study is a collaboration among SIU, the U.S. Army and Yale University.
The clinical trial is a prospective double-blind, placebo-controlled trial being conducted at Ft. Jackson, S.C. It involves 600 drill sergeant instructor trainees during their two weeks of M-16 weapons training, firing 500 rounds during a period of 11 days.
The soldiers will take either the D-met formulation or a placebo for a total of 18 days before, during and after the training. They will be assessed for hearing thresholds and tinnitus (ringing in the ears) before and two weeks after the noise exposure. The clinical trials are approved by the Food and Drug Administration and military institutional review boards. Data will be collected over a period of two years.
“As a former clinician who worked to rehabilitate patients with hearing loss and tinnitus, I am pleased to collaborate with the military to hopefully prevent this life-altering problem,” said Campbell. “To possibly bring the research from bench to bedside is very gratifying.” Campbell did her research at SIU, which owns the patents on the D-met drug.
Although the Department of Defense has had hearing conservation programs since the 1970s,including universal hearing protection (muffs and/or plugs) as well as monitoring and tracking, disability claims are increasing. The U.S. military receives more than 22,000 new claims per year for noise induced hearing loss (NIHL), which is the most common reason that U.S. troops cannot be redeployed.
“Noise-induced hearing loss and tinnitus comprise the top two injuries in terms of incidence and compensation not only Army-wide, but Department of Defense-wide. The Fort Jackson Hearing Program is committed to reducing these disabling conditions in our troops,” said Captain Rebecca Ludwig, chief of the Fort Jackson Hearing Program.
Hearing disability increases the risk of death not only for the soldiers with hearing loss but also for fellow troops because of impaired ability to communicate quickly, detect hazards or locate the enemy. NIHL is estimated to cost the Veterans Administration more than one billion dollars annually and noise-induced tinnitus (ringing in the ears) costs another one billion dollars per year. Permanent NIHL affects more than ten million Americans and work-related noise exposure affects close to 30 million. Campbell’s studies have been shown that D-Met protects against NIHL.
Campbell’s noise-induced hearing loss research previously has received $8.3 million in funding from the National Institutes of Health, DOD, and other national and international funding organizations as well as industry contracts and patent income. She has served as principal investigator for more than 60 state and federal research grants, focused primarily on ototoxicity and otoprotective agents.
Campbell joined SIU’s faculty in 1989. Previously, she was in charge of electrophysiologic measures for the otolaryngology department at the University of Iowa (1982-88), where she also completed her doctoral degree (1989). She began her career as a full-time clinician in British Columbia, starting the first audiology clinic in the Canadian Rockies for BC Public Health (1977-82). Campbell earned her master’s at the University of South Dakota (1977) and her bachelor’s at South Dakota State University (1973).
Leonard Rybak, MD, PhD is a Professor in the Division of Otolaryngology at SIU School of Medicine and specializes in ear, nose and throat whose general otolaryngology practice focuses on sinus disease and obstructive sleep apnea. He is certified by the American Board of Otolaryngology.
- Investigate the effects of toxic compounds on auditory function, morphology and biochemistry.
- Investigate potential protective agents their and mechanisms against ototoxic compounds.
- Determine the interaction between development and ototoxicity.
- Heavy Metals
- Loop Diuretics
- Aminoglycoside Antibiotics
- Endocochlear Potential (EP)
- Whole Eighth Nerve Compound Action Potential (CAP)
- Auditory Brainstem Response (ABR)
- Intracellular Potentials of the Stria Vascularis (strial potentials)
- Light Microscopy (LM)
- Scanning Electron Microscopy (SEM)
- Transmission Electron Microscopy (TEM)
- Cochlear Adenosine Receptors
- Antioxidant Enzymes
- Cochlear Glucose Metabolism
- High Pressure Liquid Chromatography Pharmacokinetics of Ototoxic Compounds
In collaboration with:
Vickram Ramkumar, PhD, Department of Pharmacology